Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

por List, A F, Bennett, J M, Sekeres, M A, Skikne, B, Fu, T, Shammo, J M, Nimer, S D, Knight, R D, Giagounidis, A
Publicado 2014

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

por List, A F, Bennett, J M, Sekeres, M A, Skikne, B, Fu, T, Shammo, J M, Nimer, S D, Knight, R D, Giagounidis, A
Publicado 2015

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

por Garcia-Manero, G, Gore, S D, Kambhampati, S, Scott, B, Tefferi, A, Cogle, C R, Edenfield, W J, Hetzer, J, Kumar, K, Laille, E, Shi, T, MacBeth, K J, Skikne, B
Publicado 2016